CRISPR/Cas9-mediated somatic and germline gene correction to restore hemostasis in hemophilia B mice

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Human Genetics

• Publication date

  2017-05-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00439-017-1801-zPMID 28508290
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 731. High-Fidelity CRISPR-Cas9 Nucleases with No Detectable Genome-Wide Off-Target Effects

  2016cited by this paper
• CRISPR/Cas9‐mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse

  2016influential reference
• CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells

  2016cited by this paper
• High-fidelity CRISPR-Cas9 variants with undetectable genome-wide off-targets

  2015cited by this paper
• Both TALENs and CRISPR/Cas9 directly target the HBB IVS2–654 (C > T) mutation in β-thalassemia-derived iPSCs

  2015cited by this paper
• In vivo genome editing of the albumin locus as a platform for protein replacement therapy.

  2015influential reference
• [A quick and efficient method to generate hemophilia B mouse models by the CRISPR/Cas system].

  2015cited by this paper
• Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins

  2014influential reference
• Author response: Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery

  2014cited by this paper
• Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery

  2014cited by this paper
• Long-term safety and efficacy of factor IX gene therapy in hemophilia B.

  2014cited by this paper
• One-step generation of different immunodeficient mice with multiple gene modifications by CRISPR/Cas9 mediated genome engineering.

  2014cited by this paper
• Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases

  2014cited by this paper
• Genotyping with CRISPR-Cas-derived RNA-guided endonucleases

  2014influential reference
• Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype

  2014influential reference
• Highly efficient gene knockout in mice and zebrafish with RNA-guided endonucleases

  2014influential reference
• Correction of a genetic disease in mouse via use of CRISPR-Cas9.

  2013cited by this paper
• Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients.

  2013cited by this paper
• An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B

  2013cited by this paper
• Robust ZFN-mediated genome editing in adult hemophilic mice.

  2013cited by this paper
• Multiplex Genome Engineering Using CRISPR/Cas Systems

  2013cited by this paper
• One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering.

  2013cited by this paper
• RNA-programmed genome editing in human cells

  2013cited by this paper
• A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity

  2012influential reference
• In vivo genome editing restores hemostasis in a mouse model of hemophilia

  2011cited by this paper
• Diagnostic guidelines for high‐resolution melting curve (HRM) analysis: An interlaboratory validation of BRCA1 mutation scanning using the 96‐well LightScanner™

  2009cited by this paper
• Minimally invasive and selective hydrodynamic gene therapy of liver segments in the pig and human

  2008cited by this paper
• Impact of non-homologous end-joining deficiency on random and targeted DNA integration: implications for gene targeting

  2008cited by this paper
• Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

  2006cited by this paper
• Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B.

  2006cited by this paper
• Hydrodynamics‐based transfection of the liver: entrance into hepatocytes of DNA that causes expression takes place very early after injection

  2004cited by this paper
• 140. Hydrodynamics-based transfection of the liver: entrance into hepatocytes of DNA that causes expression, takes place very early after injection

  2004cited by this paper
• Muscle injection of rAAV/mFIX to secrete clotting factor IX corrects the hemorrhagic tendencies in hemophilia B mice

  2003cited by this paper
• AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.

  2003cited by this paper
• Sustained expression of naked plasmid DNA encoding hepatocyte growth factor in mice promotes liver and overall body growth

  2001cited by this paper
• Definitions in Hemophilia

  2001cited by this paper
• Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis.

  2001cited by this paper
• Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system

  2000cited by this paper
• Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA

  1999influential reference
• Sustained correction of bleeding disorder in hemophilia B mice by gene therapy.

  1999cited by this paper
• Stage I Clinical Trial of Gene Therapy for Hemophilia B

  1993cited by this paper
• Stage I clinical trial of gene therapy for hemophilia B.

  1993cited by this paper
• In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs.

  1993cited by this paper
• 10 Scientific and ethical considerations in human gene therapy

  1991cited by this paper
• Scientific and ethical considerations in human gene therapy.

  1991cited by this paper
• Human gene therapy: scientific and ethical considerations.

  1985cited by this paper

• CRISPR and gene editing technologies for bleeding disorders

  2025cites this paper
• Therapeutic advances in hemophilia: from molecular innovation to patient-centered global care

  2025cites this paper
• Clinical Perspective: Advancing hemophilia treatment through gene therapy approaches.

  2025cites this paper
• Current Trends in Gene Therapy to Treat Inherited Disorders of the Brain.

  2025cites this paper
• One-step in vivo gene knock-out in porcine embryos using recombinant adeno-associated viruses

  2024cites this paper
• Various repair events following CRISPR/Cas9-based mutational correction of an infertility-related mutation in mouse embryos

  2024influential citation
• Advances in CRISPR/Cas systems-based cell and gene therapy.

  2024cites this paper
• Recent Advances in Gene Therapy for Hemophilia: Projecting the Perspectives

  2024cites this paper
• Validation for the function of protein C in mouse models

  2024cites this paper
• Hydrodynamic Delivery: Characteristics, Applications, and Technological Advances

  2023cites this paper
• Treatment of congenital coagulopathies, from biologic to biotechnological drugs: The relevance of gene editing (CRISPR/Cas).

  2023cites this paper
• Hemophilia Gene Therapy: The End of the Beginning?

  2023cites this paper
• Phenotypic variability to medication management: an update on fragile X syndrome

  2023cites this paper
• Gene Therapeutic Delivery to the Salivary Glands.

  2023cites this paper
• The most common disease-causing mutation of factor XIII deficiency is corrected by CRISPR/CAS9 gene editing system

  2022cites this paper
• Commercialization and regulation of regenerative medicine products: Promises, advances and challenges.

  2022cites this paper
• Current Therapies in Hemophilia: From Plasma-Derived Factor Modalities to CRISPR/Cas Alternatives.

  2022cites this paper
• Promoterless Gene Targeting Approach Combined to CRISPR/Cas9 Efficiently Corrects Hemophilia B Phenotype in Neonatal Mice

  2022cites this paper
• Current approaches in CRISPR-Cas9 mediated gene editing for biomedical and therapeutic applications.

  2022cites this paper
• In Vitro Assays for Comparing the Specificity of First- and Next-Generation CRISPR/Cas9 Systems.

  2021cites this paper
• Genome editing in therapy: immunological context

  2021cites this paper
• Optimizing sgRNA to Improve CRISPR/Cas9 Knockout Efficiency: Special Focus on Human and Animal Cell

  2021cites this paper
• In vivo somatic cell base editing and prime editing.

  2021cites this paper
• Therapy Development by Genome Editing of Hematopoietic Stem Cells

  2021cites this paper
• Genome editing in the human liver: Progress and translational considerations.

  2021cites this paper
• Isochorismatase domain-containing protein 1 (ISOC1) participates in DNA damage repair and inflammation-related pathways to promote lung cancer development

  2021cites this paper
• Addressing the dark matter of gene therapy: technical and ethical barriers to clinical application

  2021cites this paper
• CRISPR Guide RNA Design: Methods and Protocols

  2021cites this paper
• Hematopoietic stem cell gene therapy for the treatment of β-hemoglobinopathies

  2020cites this paper
• Biochemical mechanisms of aggregation in TGFBI-linked corneal dystrophies.

  2020cites this paper
• Genome editing technologies to treat rare liver diseases.

  2020cites this paper
• An overview of development in gene therapeutics in China

  2020cites this paper
• Haemophilia care in China: Achievements in the past decade

  2020cites this paper
• Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease

  2020cites this paper
• Beliefs and Values About Gene Therapy and In-Utero Gene Editing in Patients with Hemophilia and Their Relatives

  2020cites this paper
• Liver-directed gene-based therapies for inborn errors of metabolism

  2020cites this paper
• CRISPR-Cas systems: Overview, innovations and applications in human disease research and gene therapy

  2020cites this paper
• CRISPR/Cas9-mediated correction of mutated copper transporter ATP7B

  2020cites this paper
• In vivo Hepatocyte Genome Manipulation via Intravenous Injection of Genome Editing Components

  2020cites this paper
• Hematopoietic stem cell gene therapy: The optimal use of lentivirus and gene editing approaches.

  2019cites this paper
• Emerging Therapies for Cystic Fibrosis

  2019cites this paper
• Beliefs and Values about gene therapy and gene editing in patients with hemophilia and their family members

  2019cites this paper
• Genome‐Wide Analysis of DNA Methylation and Antituberculosis Drug‐Induced Liver Injury in the Han Chinese Population

  2019cites this paper
• A Machine Learning approach for the identification of CRISPR/Cas9 nuclease off-target for the treatment of Hemophilia

  2019cites this paper
• Molecular Mechanisms and Determinants of Innovative Correction Approaches in Coagulation Factor Deficiencies

  2019cites this paper
• Emerging gene therapies for cystic fibrosis

  2019cites this paper
• [Establishment of a stable HEK293T cell line with c.392G>T (p.131G>V) mutation site knockout in G6PD gene using CRISPR/Cas9 technique].

  2019cites this paper
• Molecular Diagnosis of Inherited Coagulation and Bleeding Disorders

  2019cites this paper
• CRISPR/Cas9-modified hematopoietic stem cells—present and future perspectives for stem cell transplantation

  2019cites this paper
• Long‐term correction of hemophilia B using adenoviral delivery of CRISPR/Cas9

  2019cites this paper
• Fluorescent labeling of CRISPR/Cas9 RNP for gene knockout in HSPCs and iPSCs reveals an essential role for GADD45b in stress response.

  2019cites this paper
• Curing hemophilia A by NHEJ-mediated ectopic F8 insertion in the mouse

  2019cites this paper
• Understanding the phenotype and preparing for therapeutics in Bardet-Biedl syndrome

  2019cites this paper
• Prospects for Cell-Directed Curative Therapy of Phenylketonuria (PKU)

  2019cites this paper
• Potentials of CRISPR in liver research and therapy.

  2019cites this paper
• Rare bleeding disorders and advances in gene therapy.

  2019cites this paper
• CRISPR technologies for stem cell engineering and regenerative medicine.

  2019cites this paper
• State-of-the-Art 2019 on Gene Therapy for Phenylketonuria

  2019cites this paper
• Intracellular generation of single-strand template increases the knock-in efficiency by combining CRISPR/Cas9 with AAV

  2018cites this paper
• CRISPR/Cas9: A tool for immunological research

  2018cites this paper
• Managing Bardet–Biedl Syndrome—Now and in the Future

  2018cites this paper
• Rescue of Fragile X Syndrome Neurons by DNA Methylation Editing of the FMR1 Gene.

  2018cites this paper
• CRISPR/Cas9 therapeutics for liver diseases

  2018cites this paper
• Editing the Genome Ex Vivo Stem Cell Therapy

  2018cites this paper
• Gene therapy for hemophilia: what does the future hold?

  2018cites this paper
• Are We There Yet? How and When Specific Biotechnologies Will Improve Human Health

  2018cites this paper
• Universitet CRISPR / Cascade 9-Mediated Genome Editing-Challenges and Opportunities

  2018cites this paper
• Gene Therapy for Hemophilia and Duchenne Muscular Dystrophy in China

  2018cites this paper
• Autologous and Heterologous Cell Therapy for Hemophilia B toward Functional Restoration of Factor IX

  2018cites this paper
• Viral Vector-Based Delivery of CRISPR/Cas9 and Donor DNA for Homology-Directed Repair in an In Vitro Model for Canine Hemophilia B

  2018cites this paper
• CRISPR/Cascade 9-Mediated Genome Editing-Challenges and Opportunities

  2018cites this paper
• Efficient In Vivo Liver-Directed Gene Editing Using CRISPR/Cas9

  2016cites this paper